不对称二甲基精氨酸与动脉粥样硬化  

Asymmetric dimethylarginine and atherosclerosis

作　　者：李建芝[1] 常青[1] 

机构地区：[1]暨南大学医学院组胚教研室,广东广州510632

出　　处：《中国病理生理杂志》2002年第5期569-572,共4页Chinese Journal of Pathophysiology

基　　金：~~

摘　　要：Asymmetric dimethylarginine(ADMA)is an endogenous inhibitor of nitric oxide synthase(NOS).it reduces nitric oxide production. ADMA is correlated with the risk factors of atherosclerosis, such as hypercholesterolemia, hypertension and hyperglycaemia. Accumulating evidence suggests that a derangement of the NOS pathway plays a critical role in atherogenesis and ADMA may participate in the process.Asymmetric dimethylarginine(ADMA)is an endogenous inhibitor of nitric oxide synthase(NOS).it reduces nitric oxide production. ADMA is correlated with the risk factors of atherosclerosis, such as hypercholesterolemia, hypertension and hyperglycaemia. Accumulating evidence suggests that a derangement of the NOS pathway plays a critical role in atherogenesis and ADMA may participate in the process.

关 键 词：不对称二甲基精氨酸 动脉粥样硬化 一氧化氮合酶 一氧化氮 

分 类 号：R543.5[医药卫生—心血管疾病]